To address these knowledge gaps, we conducted this study with the aim to assess the temporal patterns of and disparities in adjuvant chemotherapy use in early-stage HR-positive, ERBB2-negative breast cancer by age, genomic risk, and nodal involvement. This evidence concerns the gene ERBB2 and breast cancer.